Short-term prognostic value of serum neuron specific enolase and S100B in acute stroke patients

González-García, Sergio; González‐Quevedo, Alina; Fernández-Concepción, O; Peña-Sánchez, Marisol; Menéndez-Saínz, Caridad; Hernández-Díaz, Zenaida; Arteche-Prior, Marianela; Pando-Cabrera, A; Fernández-Novales, Carlos

doi:10.1016/j.clinbiochem.2012.07.094

Cited by 64 publications

(48 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Brain biomarkers have different patterns of release and limitations to their use 14,15 . As a result, clinical applicability may be limited by type of brain injury (i.e., trauma, stroke, hypoxia-ischemia, cardiopulmonary bypass) 16–20 . A prospective pilot study involving pediatric subjects who received 24 hours of therapeutic hypothermia found that serum NSE and S100b had excellent specificity and fair sensitivity at 48 hours or later to predict outcome at hospital discharge 10 .…”

Section: Introductionmentioning

confidence: 99%

Serum Biomarkers of Brain Injury to Classify Outcome After Pediatric Cardiac Arrest*

Fink

Berger

Clark

et al. 2014

Critical Care Medicine

View full text Add to dashboard Cite

Objective Morbidity and mortality in children with cardiac arrest (CA) largely result from neurologic injury. Serum biomarkers of brain injury can potentially measure injury to neurons (neuron specific enolase [NSE]), astrocytes (S100b), and axons (myelin basic protein [MBP]). We hypothesized that serum biomarkers can be used to predict outcome from pediatric CA. Design Prospective observational study. Setting Single tertiary pediatric hospital. Patients Forty-three children with cardiac arrest. Interventions None. Measurements and Main Results We measured serum NSE, S100b, and MBP on days 1–4 and 7 after CA. We recorded demographics, details of the CA and resuscitation, and Pediatric Cerebral Performance Category (PCPC) at hospital discharge and 6 months. We analyzed the association of biomarker levels at 24, 48, and 72 hours with good (PCPC 1–3) or poor (PCPC 4–6) outcome and mortality. Forty-three children (49% female; mean age of 5.9 ± 6.3 were enrolled and 17 (40%) died. Serum concentration at 24 hours for all 3 biomarkers predicted mortality (all p<0.05). Additionally, serum NSE and S100b concentrations were increased in the poor outcome vs. good outcome group and in subjects who died at all time points (all p<0.05). Receiver operator curves for serum S100b and NSE to predict good vs. poor outcome at 6 months was superior to clinical predictors. There was no association between serum biomarker concentrations and subject temperature. Conclusions Preliminary data show that serum S100b, NSE, and MBP may aid in outcome prediction of children surviving CA.

show abstract

Section: Introductionmentioning

confidence: 99%

Serum Biomarkers of Brain Injury to Classify Outcome After Pediatric Cardiac Arrest*

Fink

Berger

Clark

et al. 2014

Critical Care Medicine

View full text Add to dashboard Cite

show abstract

“…(34,35) González-García et al found significantly elevated serum concentrations of NSE and S100 beta in patients with arterial ischemic stroke (AIS) compared with the control group (NSE: 11.2 µmol/L versus 9.5 µmol/L, with p=0.0135; S100 beta: 127 nmol/L versus 84.6 nmol/L, with p=0.0000). (36) …”

Section: Discussionmentioning

confidence: 99%

Biomarcadores na encefalopatia séptica: revisão sistemática dos estudos clínicos

Zenaide¹,

Gusmao-Flores²

2013

Rev. bras. ter. intensiva

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to systematically review the importance of neuron-specific enolase and S100 beta for diagnosing and monitoring septic encephalopathy. MethodsA PubMed database search was performed to identify studies that evaluated S100 beta and neuron-specific enolase serum levels in patients with sepsis and that were published between January 2000 and April 2012. Only human studies that employed an additional method of neurological assessment were selected. ResultsNine studies were identified, seven of which associated high concentrations of S100 beta and neuron-specific enolase with the development of septic encephalopathy. Four studies also associated these concentrations with increased mortality. However, two studies did not find such an association when they evaluated S100 beta levels, and one of these studies did not observe a correlation between neuron-specific enolase and septic encephalopathy. ConclusionS100 beta and neuron-specific enolase are promising biomarkers for diagnosing and monitoring patients with septic encephalopathy, but more research is necessary.

show abstract

“…González-García et al had recently observed that the levels of NSE in serum samples of acute stroke patients were significantly higher than in controls. [6] In the control group, the mean serum NSE level in males was 2.46±2.27 ng/ml and in females was 1.84±1.81 ng/ml. Mean serum levels of NSE in cases were found to be 89.18±46.89 ng/ml on day 1 and 91.76±51.30 ng/ml on day 7.…”

Section: Discussionmentioning

confidence: 99%

A study on Neuron Specific Enolase (NSE) in cerebrovascular stroke patients

Motiani¹,

H²,

Kakkar³

2017

Ann. Int. Med. Den.Res.

View full text Add to dashboard Cite

Background: Biochemical markers of acute neuronal injury may aid in the diagnosis and management of cerebrovascular stroke. Neuron specific enolase (NSE) is one such marker which is released in the blood in acute neuronal injury and can be estimated in the serum of patients to assess the short-term neurological outcome. This study was carried out on patients of acute cerebrovascular stroke with the aim to compare NSE levels in normal subjects with that in cerebrovascular stroke patients. Methods: 60 subjects investigated in the study included 30 cerebrovascular stroke patients who were admitted within 72 hours of onset of stroke symptoms, in the Emergency Department and the Department of Neurology at HIMS, and 30 healthy controls. Serum NSE levels of cases and controls were determined on day 1 and day 7 using DRG-NSE ELISA kit. Statistical analysis was performed using the unpaired 't' test on SPSS software for windows version 17.0 Results: There was a significant difference in the levels of serum NSE between cases and controls (p<0.001).The mean levels of serum NSE in controls were 2.25±2.12 ng/ml and in cases at the time of admission were 89.18±46.89 ng/ml . The normal range of serum NSE is 0-12 ng/ml. It was also observed that the levels of serum NSE showed no difference in males or females or among different age groups. Conclusion: This study showed that estimation of serum NSE levels can be used as an early marker of neuronal damage in acute cerebrovascular stroke patients.

show abstract

Short-term prognostic value of serum neuron specific enolase and S100B in acute stroke patients

Cited by 64 publications

References 27 publications

Serum Biomarkers of Brain Injury to Classify Outcome After Pediatric Cardiac Arrest*

Serum Biomarkers of Brain Injury to Classify Outcome After Pediatric Cardiac Arrest*

Biomarcadores na encefalopatia séptica: revisão sistemática dos estudos clínicos

A study on Neuron Specific Enolase (NSE) in cerebrovascular stroke patients

Contact Info

Product

Resources

About